The brand drug has never been fully characterized ... the agency also requested that manufacturers demonstrate equivalent immunogenicity for generic enoxaparin. Again, it stopped short of ...
The health system will still use other distributors and companies to stock brand name medications and biological drugs like insulin, gene therapies, monoclonal antibodies and others that don’t have ...